Galanin peptide family as a modulating target for contribution to metabolic syndrome

General and Comparative Endocrinology

Volumn 179, Issue 1, 2012, Pages 115-120

  Fang, Penghua ^a,b   Yu, Mei ^b   Shi, Mingyi ^b   Zhang, Zhenwen ^b   Sui, Yumei ^b   Guo, Lili ^b   Bo, Ping ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b YANGZHOU UNIVERSITY   (China)

Author keywords

Galanin; Metabolic syndrome; Type 2 diabetes

Indexed keywords

ALARIN; GALANIN; GALANIN LIKE PEPTIDE; GALANIN RECEPTOR; GLUCOSE; MESSENGER RNA; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEEDING BEHAVIOR; FOOD INTAKE; FOOD PREFERENCE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; METABOLIC SYNDROME X; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84865617525     PISSN: 00166480     EISSN: 10956840     Source Type: Journal    
DOI: 10.1016/j.ygcen.2012.07.029     Document Type: Review

References (96)

1. Abbott S.B., Pilowsky P.M. Galanin microinjection into rostral ventrolateral medulla of the rat is hypotensive and attenuates sympathetic chemoreflex. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R1019-R1026.
2. Abete I., Goyenechea E., Zulet M.A., Marti{dotless}́nez J.A. Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutr. Metab. Cardiovasc. Dis. 2011, 21:B1-B15.
3. Adams A.C., Clapham J.C., Wynick D., Speakman J.R. Feeding behaviour in galanin knockout mice supports a role of galanin in fat intake and preference. J. Neuroendocrinol. 2008, 20:199-206.
4. Adeghate E., Ponery A.S. Large reduction in the number of galanin-immunoreactive cells in pancreatic islets of diabetic rats. Neuroendocrinology 2001, 13:706-710.
5. Ahren B., Pacini G., Wynick D., Wierup N., Sundler F. Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. Endocrinology 2004, 145:3190-3196.
6. Augustin R. The protein family of glucose transport facilitators: It's not only about glucose after all. IUBMB Life 2010, 62:315-333.
7. Barson J.R., Karatayev O., Gaysinskaya V., Chang G.Q., Leibowitz S.F. Effect of dietary fatty acid composition on food intake, triglycerides, and hypothalamic peptides. Regul. Pept. 2012, 173:13-20.
8. Berger A., Lang R., Moritz K., Santic R., Hermann A., Sperl W., Kofler B. Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. Endocrinology 2004, 145:500-507.
9. Blackshear A., Yamamoto M., Anderson B.J., Holmes P.V., Lundström L., Langel U., Robinson J.K. Intracerebroventricular administration of galanin or galanin receptor subtype 1 agonist M617 induces c-Fos activation in central amygdala and dorsomedial hypothalamus. Peptides 2007, 28:1120-1124.
10. Boughton C.K., Patterson M., Bewick G.A., Tadross J.A., Gardiner J.V., Beale K.E., Chaudery F., Hunter G., Busbridge M., Leavy E.M., Ghatei M.A., Bloom S.R., Murphy K.G. Alarin stimulates food intake and gonadotrophin release in male rats. Br. J. Pharmacol. 2010, 161:601-613.
11. Bruce K.D., Hanson M.A. The developmental origins, mechanisms, and implications of metabolic syndrome. J. Nutr. 2010, 140:648-652.
12. Cho L.W. Metabolic syndrome. Singapore Med. J. 2011, 52:779-785.
13. Coelho E.F., Ferrari M.F., Maximino J.R., Chadi G., Fior-Chadi D.R. Decreases in the expression of CGRP and galanin mRNA in central and peripheral neurons related to the control of blood pressure following experimental hypertension in rats. Brain Res. Bull. 2004, 64:59-66.
14. Corwin R.L., Robinson J.K., Crawley J.N. Galanin antagonists block galanin induced feeding in the hypothalamus and amygdala of the rat. Eur. J. Neurosci. 1993, 5:1528-1533.
15. Crawley J.N., Austin M.C., Fiske S.M., Martin B., Consolo S., Berthold M., Langel U., Fisone G., Bartfai T. Activity of centrally administered galanin fragments on stimulation of feeding behavior and on galanin receptor binding in the rat hypothalamus. J. Neurosci. 1990, 10:3695-3700.
16. de Pedro N., Céspedes M.V., Delgado M.J., Alonso-Bedate M. The galanin induced feeding stimulation is mediated via alpha 2-adrenergic receptors in goldfish. Regul. Pept. 1995, 57:77-84.
17. Di{dotless}́az-Cabiale Z., Narváez J.A., Yanaihara N., González-Barón S., Fuxe K. Galanin/alpha2-receptor interactions in central cardiovascular control. Neuropharmacology 2000, 39:1377-1385.
18. Díaz-Cabiale Z., Parrado C., Fuxe K., Agnati L., Narváez J.A. Receptor-receptor interactions in central cardiovascular regulation. Focus on neuropeptide/a2-adrenoreceptor interactions in the nucleus tractus solitarius. J. Neural. Transm. 2007, 114:115-125.
19. Díaz-Cabiale Z., Parrado C., Narváez M., Millón C., Puigcerver A., Fuxe K., Narváez J.A. The Galanin N-terminal fragment (1-15) interacts with neuropeptide Y in central cardiovascular control: involvement of the NPY Y2 receptor subtype. Regul. Pept. 2010, 163:130-136.
20. Díaz-Cabiale Z., Parrado C., Rivera A., de la Calle A., Agnati L., Fuxe K., Narváez J.A. Galanin-neuropeptide Y (NPY) interactions in central cardiovascular control: involvement of the NPY Y receptor subtype. Eur. J. Neurosci. 2006, 24:499-508.
21. Díaz-Cabiale Z., Parrado C., Vela C., Razani H., Coveñas R., Fuxe K., Narváez J.A. Role of galanin and galanin(1-15) on central cardiovascular control. Neuropeptides 2005, 39:185-190.
22. Díaz-Cabiale Z., Parrado C., Vela C., Coveñas R., Yanaihara N., Fuxe K., González-Barón S., Narváez J.A. Intracisternal galanin/angiotensin II interactions in central cardiovascular control. Regul. Pept. 2005, 127:133-140.
23. Druet C., Ong K., LevyMarchal C. Metabolic syndrome in children: comparison of the International Diabetes Federation Consensus with an adapted National Cholesterol Education Program definition in 300 overweight and obese French children. Horm. Res. Paediatr. 2007, 73(2010):181-186.
24. Dungan Lemko H.M., Clifton D.K., Steiner R.A., Fraley G.S. Altered response to metabolic challenges in mice with genetically targeted deletions of galanin-like peptide. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E605-E612.
25. Eberhard N., Mayer C., Santic R., Navio R.P., Wagner A., Bauer H.C., Sperk G., Boehm U., Kofler B. Distribution of alarin immunoreactivity in the mouse brain. J. Mol. Neurosci. 2011, 46:18-32.
26. Fang P.H., Yu M., Ma Y.P., Li J., Sui Y.M., Shi M.Y. Central nervous system regulation of food intake and energy expenditure: role of galanin-mediated feeding behavior. Neurosci. Bull. 2011, 27:407-412.
27. Fang P., Yu M., Guo L., Bo P., Zhang Z., Shi M. Galanin and its receptors: a novel strategy for appetite control and obesity therapy. Peptides 2012, 36:331-339.
28. Florén A., Land T., Langel ü. Galanin receptor subtypes and ligand binding. Neuropeptides 2000, 34:331-337.
29. Foster M.T., Shi H., Seeley R.J., Woods S.C. Removal of intra-abdominal visceral adipose tissue improves glucose tolerance in rats: role of hepatic triglyceride storage. Physiol. Behav. 2011, 104:845-854.
30. Fraley G.S. Immunolesions of glucoresponsive projections to the arcuate nucleus alter glucoprivic-induced alterations in food intake, luteinizing hormone secretion, and GALP mRNA, but not sex behavior in adult male rats. Neuroendocrinology 2006, 83:97-105.
31. Fraley G.S., Leathley E., Lundy N., Chheng E., King I., Kofler B. Effects of alarin on food intake, body weight and luteinizing hormone secretion in male mice. Neuropeptides 2012, 46:99-104.
32. Fraley G.S., Scarlett J.M., Shimada I., Teklemichael D.N., Acohido B.V., Clifton D.K., Steiner R.A. Effects of diabetes and insulin on the expression of galanin-like peptide in the hypothalamus of the rat. Diabetes 2004, 53:1237-1242.
33. Gottsch M.L., Clifton D.K., Steiner R.A. Galanin-like peptide as a link in the integration of metabolism and reproduction. Trends Endocrinol. Metab. 2004, 15:215-221.
34. Gottsch M.L., Zeng H., Hohmann J.G., Weinshenker D., Clifton D.K., Steiner R.A. Phenotypic analysis of mice deficient in the type 2 galanin receptor (GALR2). Mol. Cell Biol. 2005, 25:4804-4811.
35. Guo L., Shi M., Zhang L., Li G., Zhang L., Shao H., Fang P., Li J., Ma Y., Shi Q., Sui Y. Galanin antagonist increases insulin resistance by reducing glucose transporter 4 effect in adipocytes of rats. Gen. Comp. Endocrinol. 2011, 173:159-163.
36. He B., Shi M., Zhang L., Li G., Zhang L., Shao H., Li J., Fang P., Ma Y., Shi Q., Sui Y. Beneficial effect of galanin on insulin sensitivity in muscle of type 2 diabetic rats. Physiol. Behav. 2011, 103:284-289.
37. Hedlund P.B., Aguirre J.A., Narvaez J.A., Fuxe K. Centrally coinjected galanin and a5-HT1A agonist act synergistically to produce vasodepressor responses in the rat. Eur. J. Pharmacol. 1991, 204:87-95.
38. Holmberg K., Kuteeva E., Brumovsky P., Kahl U., Karlström H., Lucas G.A., Rodriguez J., Westerblad H., Hilke S., Theodorsson E., Berge O.G., Lendahl U., Bartfai T., Hökfelt T. Generation and phenotypic characterization of a galanin overexpressing mouse. Neuroscience 2005, 133:59-77.
39. Izdebska K., Ciosek J. Galanin influences on vasopressin and oxytocin release: in vitro studies. Neuropeptides 2010, 44:341-348.
40. Jiang L., Shi M., Guo L., He B., Li G., Zhang L., Zhang L., Shao H. Effect of M35, a neuropeptide galanin antagonist on glucose uptake translated by glucose transporter 4 in trained rat skeletal muscle. Neurosci. Lett. 2009, 467:178-181.
41. 2 and its new analogues on glucose-induced insulin secretion. Pol. J. Pharmacol. 2002, 54:133-141.
42. Karatayev O., Baylan J., Leibowitz S.F. Increased intake of ethanol and dietary fat in galanin overexpressing mice. Alcohol 2009, 43:571-580.
43. Karatayev O., Baylan J., Weed V., Chang S., Wynick D., Leibowitz S.F. Galanin knockout mice show disturbances in ethanol consumption and expression of hypothalamic peptides that stimulate ethanol intake. Alcohol Clin. Exp. Res. 2010, 34:72-80.
44. Kidambi S., Kotchen J.M., Krishnaswami S., Grim C.E., Kotchen T.A. Cardiovascular correlates of insulin resistance in normotensive and hypertensive African Americans. Metabolism 2011, 60:835-842.
45. Kim A.R., Park T.S. Diet-induced obesity regulates the galanin-mediated signaling cascade in the adipose tissue of mice. Mol. Nutr. Food Res. 2010, 54:1361-1370.
46. Krasnow S.M., Hohmann J.G., Gragerov A., Clifton D.K., Steiner R.A. Analysis of the contribution of galanin receptors 1 and 2 to the central actions of galanin like peptide. Neuroendocrinology 2004, 79:268-277.
47. Kyrkouli S.E., Strubbe J.H., Scheurink A.J. Galanin in the PVN increases nutrient intake and changes peripheral hormone levels in the rat. Physiol. Behav. 2006, 89:103-109.
48. Lang R., Gundlach A.L., Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol. Ther. 2007, 115:177-207.
49. Lang R., Kofler B. The galanin peptide family in inflammation. Neuropeptides 2011, 45:1-8.
50. Lawrence C., Fraley G.S. Galanin-like peptide (GALP) is a hypothalamic regulator of energy homeostasis and reproduction. Front. Neuroendocrinol. 2011, 32:1-9.
51. Legakis I., Mantzouridis T., Mountokalakis T. Positive correlation of galanin with glucose in type 2 diabetes. Diabetes Care 2005, 28:759-760.
52. Legakis I.N. The role of galanin in metabolic disorders leading to type 2 diabetes mellitus. Drug News Perspect 2005, 18:173-177.
53. Legalkis I.N., Mantzouridis T., Mountokalakis T. Positive correlation of galanin with glucose in healthy volunteers during an oral glucose tolerance test. Horm. Metab. Res. 2007, 39:53-55.
54. Leibowitz S.F., Akabayashi A., Wang J. Obesity on a high-fat diet: role of hypothalamic galanin in neurons of the anterior paraventricular nucleus projecting to the median eminence. J. Neurosci. 1998, 18:2709-2719.
55. Leibowitz S.F., Dourmashkin J.T., Chang G.Q., Hill J.O., Gayles E.C., Fried S.K., Wang J. Acute high-fat diet paradigms link galanin to triglycerides and their transport and metabolism in muscle. Brain Res. 2004, 1008:168-178.
56. Leto D., Saltiel A.R. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell. Biol. 2012, 13:383-396.
57. Liang Y., Sheng S., Fang P., Ma Y., Li J., Shi Q., Sui Y., Shi M. Exercise-induced galanin release facilitated GLUT4 translocation in adipocytes of type 2 diabetic rats. Pharmacol. Biochem. behav. 2012, 100:554-559.
58. Li R.Y., Song H.D., Shi W.J., Hu S.M., Yang Y.S., Tang J.F., Chen M.D., Chen J.L. Galanin inhibits leptin expression and secretion in rat adipose tissue and 3T3-L1 adipocytes. J. Mol. Endocrinol. 2004, 33:11-19.
59. Lundström L., Sollenberg U., Brewer A., Kouya P.F., Zheng K., Xu X., Sheng X., Robinson J.K., Wiesenfeld-Hallin Z., Xu Z., Hokfelt T., Bartfai T., Langel U. A galanin receptor subtype 1 specific agonist. Int. J. Peptide Res. Therap. 2005, 11:15-25.
60. Malmlöf K., Fledelius C., Johansen T., Theodorsson E. The anorectic response to growth hormone in obese rats is associated with an increased rate of lipid oxidation and decreased hypothalamic galanin. Physiol. Behav. 2011, 102:459-465.
61. Man P.S., Lawrence C.B. The effects of galanin-like peptide on energy balance, body temperature and brain activity in the mouse and rat are independent of the GALR2/3 receptor. J. Neuroendocrinol. 2008, 20:128-137.
62. Manabe T., Okada Y., Sawai H. Effect of galanin on plasma glucose, insulin and pancreatic glucagon in dogs. J. Int. Med. Res. 2003, 31:126-132.
63. Mitchell A.L. How obesity causes diabetes: not a tall tale. Science 2005, 307:373-375.
64. Narváez J.A., Díaz-Cabiale Z., Hedlund P.B., Aguirre J.A., Coveñas R., González-Barón S., Fuxe K. The galanin receptor antagonist M40 blocks the central cardiovascular actions of the galanin N-terminal fragment (1-15). Eur. J. Pharmacol. 2000, 399:197-203.
65. Narváez J.A., Di{dotless}́az Z., Aguirre J.A., González-Barón S., Yanaihara N., Fuxe K., Hedlund P.B. Intracisternally injected galanin-(1-15) modulates the cardiovascular responses of galanin-(1-29) and the 5-HT1A receptor agonist 8-OH-DPAT. Eur. J. Pharmacol. 1994, 257:257-265.
66. Oak S.A., Tran C., Pan G., Thamotharan M., Devaskar S.U. Perturbed skeletal muscle insulin signaling in the adult female intrauterine growth-restricted rat. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E1321-E1330.
67. Ohtaki T., Kumano S., Ishibashi Y., Ogi K., Matsui H., Harada M., Kitada C., Kurokawa T., Onda H., Fujino M. Isolation and cDNA cloning of a novel galanin-like peptide (GALP) from porcine hypothalamus. J. Biol. Chem. 1999, 274:37041-37045.
68. Oka R., Kobayashi J., Inazu A., Yagi K., Miyamoto S., Sakurai M., Nakamura K., Miura K., Nakagawa H., Yamagishi M. Contribution of visceral adiposity and insulin resistance to metabolic risk factors in Japanese men. Metabolism 2010, 59:748-754.
69. Ozanne S.E., Olsen G.S., Hansen L.L., Tingey K.J., Nave B.T., Wang C.L., Hartil K., Petry C.J., Buckley A.J., Mosthaf-Seedorf L. Early growth restriction leads to down regulation of protein kinase C zeta and insulin resistance in skeletal muscle. J. Endocrinol. 2003, 177:235-241.
70. Pankov Iu.A., Chekhranova M.K., Karpova S.K. The interconnections of molecular mechanisms of hormone actions and their role in pathogenesis of obesity, insulin resistance, and diabetes mellitus. Vestn. Ross. Akad. Med. Nauk. 2008, 3:28-36.
71. Plaisier C.L., Kyttälä M., Weissglas-Volkov D., Sinsheimer J.S., Huertas-Vazquez A., Riba L., Ramírez-Jiménez S., de Bruin T.W., Tusié-Luna T., Aouizerat B.E., Pullinger C.R., Malloy M.J., Kane J.P., Cruz-Bautista I., Herrera M.F., Aguilar-Salinas C., Kuusisto J., Laakso M., Taskinen M.R., van der Kallen C.J., Pajukanta P. Galanin preproprotein is associated with elevated plasma triglycerides. Arterioscler. Thromb. Vasc. Biol. 2009, 29:147-152.
72. Poritsanos N.J., Mizuno T.M., Lautatzis M.E., Vrontakis M. Chronic increase of circulating galanin levels induces obesity and marked alterations in lipid metabolism similar to metabolic syndrome. Int. J. Obes (Lond.) 2009, 33:1381-1389.
73. Qi L., Saberi M., Zmuda E., Wang Y., Altarejos J., Zhang X., Dentin R., Hedrick S., Bandyopadhyay G., Hai T., Olefsky J., Montminy M. Adipocyte CREB promotes insulin resistance in obesity. Cell Metab. 2009, 9:277-286.
74. Ruczynsk J., Cybal M., Wojcikowskib C., Rekowski P. Effects of porcine galanin, galanin (1-15) NH2 and its new analogues on glucose-induced insulin secretion. Pol. J. Pharmacol. 2003, 54:133-141.
75. Runesson J., Saar I., Lundström L., Järv J., Langel U. A novel GalR2-specific peptide agonist. Neuropeptides 2009, 43:187-192.
76. Saar I., Runesson J., McNamara I., Järv J., Robinson J.K., Langel U. Novel galanin receptor subtype specific ligands in feeding regulation. Neurochem. Int. 2011, 58:714-720.
77. Santic R., Fenninger K., Graf K., Schneider R., Hauser-Kronberger C., Schilling F.H., Kogner P., Ratschek M., Jones N., Sperl W., Kofler B. Gangliocytes in neuroblastic tumors express alarin, a novel peptide derived by differential splicing of the galanin-like peptide gene. J. Mol. Neurosci. 2006, 29:145-152.
78. Santic R., Schmidhuber S.M., Lang R., Rauch I., Voglas E., Eberhard N., Bauer J.W., Brain S.D., Kofler B. Alarin is a vasoactive peptide. Proc. Natl. Acad. Sci. USA 2007, 104:10217-10222.
79. Scott M.K., Ross T.M., Lee D.H., Wang H.Y., Shank R.P., Wild K.D., Davis C.B., Crooke J.J., Potocki A.C., Reitz A.B. 2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor. Bioorg. Med. Chem. 2000, 8:1383-1391.
80. Sollenberg U.E., Lundstrom L., Bartfai T., Langel U. M871-A novel peptide antagonist selectively recognizing the galanin receptor Type 2. Int. J. Peptide Res. Ther. 2006, 12:115-119.
81. Swanson C.J., Blackburn T.P., Zhang X., Zheng K., Xu Z.Q., Hökfelt T., Wolinsky T.D., Konkel M.J., Chen H., Zhong H., Walker M.W., Craig D.A., Gerald C.P., Branchek T.A. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc. Natl. Acad. Sci. USA 2005, 102:17489-17494.
82. Sweeney G., Keen J., Somwar R., Konrad D., Garg R., Klip A. High leptin levels acutely inhibit insulin-stimulated glucose uptake without affecting glucose transporter 4 translocation in L6 rat skeletal muscle. Endocrinology 2001, 142:4806-4812.
83. Tachibana T., Mori M., Khan M.S., Ueda H., Sugahara K., Hiramatsu K. Central administration of galanin stimulates feeding behavior in chicks. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2008, 151:637-640.
84. Tang G., Wang Y., Park S., Bajpayee N.S., Vi D., Nagaoka Y., Birnbaumer L., Jiang M. Go2 G protein mediates galanin inhibitory effects on insulin release from pancreatic β cells. Proc. Natl. Acad. Sci. USA 2012, 109:2636-2641.
85. Tatemoto K., Rökaeus A., Jörnvall H., McDonald T.J., Mutt V. Galanin-a novel biologically active peptide from porcine intestine. FEBS Lett. 1983, 164:124-128.
86. Tempel D.L., Leibowitz K.J., Leibowitz S.F. Effects of PVN galanin on macronutrient selection. Peptides 1988, 9:309-314.
87. Thong F.S., Bilan P.J., Klip A. The Rab GTPase-activating protein AS160 integrates Akt, Protein Kinase C, and AMP-activated protein kinase signals regulating GLUT4 traffic. Diabetes 2007, 56:414-423.
88. Van Der Kolk N., Madison F.N., Mohr M., Eberhard N., Kofler B., Fraley G.S. Alarin stimulates food intake in male rats and LH secretion in castrated male rats. Neuropeptides 2010, 44:333-340.
89. Wang J., Akabayashi A., Yu H.J., Dourmashkin J., Alexander J.T., Silva I., Lighter J., Leibowitz S.F. Hypothalamic galanin: control by signals of fat metabolism. Brain Res. 1998, 804:7-20.
90. Wang S., Ghibaudi L., Hashemi T., He C., Strader C., Bayne M., Davis H., Hwa J.J. The GalR2 galanin receptor mediates galanin-induced jejunal contraction, but not feeding behavior, in the rat: differentiation of central and peripheral effects of receptor subtype activation. FEBS Lett. 1998, 434:277-282.
91. Wang S., Hashemi T., Fried S., Clemmons A.L., Hawes B.E. Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 1998, 37:6711-6717.
92. Wang S., He C., Maguire M.T., Clemmons A.L., Burrier R.E., Guzzi M.F., Strader C.D., Parker E.M., Bayne M.L. Genomic organization and functional characterization of the mouse GalR1 galanin receptor. FEBS Lett. 1997, 411:225-230.
93. Wood I.S., de Heredia F.P., Wang B., Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc. Nutr. Soc. 2009, 68:370-377.
94. Yun R., Dourmashkin J.T., Hill J., Gayles E.C., Fried S.K., Leibowitz S.F. PVN galanin increases fat storage and promotes obesity by causing muscle to utilize carbohydrate more than fat. Peptides 2005, 26:2265-2273.
95. Zhang Z., Sheng S., Guo L., Li G., Zhang L., Zhang L., Shi M., Bo P., Zhu Y. Intracerebroventricular administration of galanin antagonist sustains insulin resistance in adipocytes of type 2 diabetic trained rats. Mol. Cell Endocrinol. 2012, 361:213-218.
96. Zorrilla E.P., Brennan M., Sabino V., Lu X., Bartfai T. Galanin type 1 receptor knockout mice show altered responses to high-fat diet and glucose challenge. Physiol. Behav. 2007, 91:479-485.